Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2002 March;44(1) > Panminerva Medica 2002 March;44(1):41-5

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

REVIEW ARTICLES   

Panminerva Medica 2002 March;44(1):41-5

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

The advancement of cancer chemoprevention by revision of clinical trial strategies

Sharma R. A.

From the Cancer Biomarkers and Prevention Group Oncology Department University of Leicester Leicester, UK


PDF


After a quar­ter of a cen­tu­ry of rap­id advanc­es in can­cer ­research, the ­focus of onco­log­i­cal ­drug devel­op­ment has shift­ed ­from cyto­tox­ic chem­o­ther­a­py to ration­al­ly ­designed ­agents ­that tar­get spe­cif­ic mole­cules asso­ciat­ed ­with malig­nant ­cells or ­their envi­ron­ment. As a con­se­quence of great­er pub­lic aware­ness of ­health relat­ed ­issues and pop­u­la­tion screen­ing, the detec­tion of ear­ly can­cer or prem­a­lig­nant ­lesions has dem­on­strat­ed the poten­tial ­that ­exists for tar­get­ing the ­same mole­cules dur­ing car­cin­o­gen­e­sis. One meth­od of ­such inter­ven­tion is chem­o­pre­ven­tion, the inhi­bi­tion, retar­da­tion or rever­sal of car­cin­o­gen­ic pro­cess­es by chem­i­cal ­means. Tamoxifen and cel­e­cox­ib ­have ­been ­licensed in the USA for the chem­o­pre­ven­tion of ­breast and color­ec­tal can­cers respec­tive­ly in cer­tain ­well-­defined “at ­risk” indi­vid­u­als. Unfortunately, ­many ­large-­scale can­cer chem­o­pre­ven­tion ­trials ­have yield­ed neg­a­tive ­results, and a few may ­even ­have ­caused ­harm to ­healthy indi­vid­u­als con­sid­ered at ­risk of devel­op­ing can­cer. In ­this arti­cle, the impor­tance of not put­ting the ­cart ­before the ­horse is ­argued. In par­tic­u­lar, two fac­tors in chem­o­pre­ven­tive ­agent devel­op­ment ­will be empha­sised: phase I/II stud­ies in ­patients ­with can­cer or ­patients at ­risk of sec­ond pri­mary ­tumors and the val­i­da­tion and incor­po­ra­tion of bio­mark­ers of car­cin­o­gen­e­sis ­from the ear­li­est phas­es of clin­i­cal devel­op­ment. This struc­tured ­approach cur­rent­ly emerg­ing is pro­vid­ing phar­mac­o­log­i­cal and mechan­is­tic ­data on nov­el ­agents ­which ­will ­prove essen­tial in the plan­ning of larg­er-­scale com­mit­ments.

top of page